Released on: March 28, 2008, 4:54 pm

Press Release Author: GTCbio

Industry: Biotech

Press Release Summary: Dr. John W. Cuozzo, Director of ELT Lead Discovery at
GlaxoSmithKline will present at GTCbio's 3rd Assay Development & Screening
Technologies Conference on June 5-6, 2008 in San Francisco, CA. Dr. Cuozzo will
speak on selecting hits from billions of compounds from encoded library technology.


Press Release Body: Dr. John W. Cuozzo, Director of ELT Lead Discovery at
GlaxoSmithKline will present at GTCbio's 3rd Assay Development & Screening
Technologies Conference on June 5-6, 2008 in San Francisco, CA. Dr. Cuozzo will
speak on selecting hits from billions of compounds from encoded library technology.

Recent technological advancements have improved the speed and reliability of high
throughput screening but the total number of compounds that can be assayed using
these methods has remained in the 10^6 range. Aptamer, phage, and antibody screening
libraries have significantly greater diversity and can be rapidly queried for hits
by selection. Encoded Library Technology (ELT) combines the power of affinity based
enrichment with combinatorial chemistry to enable the rapid selection of hits from
small molecule libraries containing up to several billion compounds. Each ELT
library molecule carries a unique DNA tag which encodes the chemical composition of
the small molecule. Libraries are \"selected\" against protein targets by affinity
based methods. Enriched binders are isolated, sequenced, and translated back into
their corresponding chemical structures. The hit compounds are then synthesized
without the DNA tag and assayed for activity against the target. The presentation
will describe how Dr. Cuozzo and his group have applied this technology to rapidly
discover potent and selective hits against several different classes of drug target,
and how they are continuing to refine their methods to improve success rate and
focus selections on compounds with novel mechanisms of action.

GTCbio\'s 3rd Assay Development and Screening Technologies conference will provide
attendees with critical information to utilize in the discovery and development of
assays, while keeping them informed about the latest screening technologies for both
high-throughput screening and high-content screening. Topics being covered include
cell based assays, high throughput screening, high content screening, in vitro
assays and screening, novel assay and screening technologies, and target validation.
For more information visit www.gtcbio.com.
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical
industries. Our goal is to facilitate the exchange of biopharmaceutical and
biomedical intelligence between industry leaders, academic and government
organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company
founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, nina.tran@gtcbio.com


Web Site: http://www.gtcbio.com

Contact Details: Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax,
nina.tran@gtcbio.com
434 W. Foothill Blvd
Monrovia, CA 91016